Cell Penetrating Bispecific Antibodies for Targeting Oncogenic Transcription Factors in Advanced Prostate Cancer
Technical Report,30 Sep 2012,29 Sep 2016
Medical University of South Carolina Charleston United States
Pagination or Media Count:
The goal of these studies is to develop and validate cell-penetrating bi-specific antibodies as an agent that can selectively inhibit the function of intracellular proteins. We have developed 3E10-AR441 bi-specific antibody to inhibit the function both ligand-dependent and independent forms of the androgen receptor AR, key drivers of prostate carcinogenesis.
- Medicine and Medical Research